Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. - Wikidata - awgldk - TriplyDB

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.

http://www.wikidata.org/entity/Q38460330

about

Are we there yet? The smallpox research agenda using variola virus Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies Cytomegalovirus antivirals and development of improved animal models Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver.Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.Application of the Ibis-T5000 pan-Orthopoxvirus assay to quantitatively detect monkeypox viral loads in clinical specimens from macaques experimentally infected with aerosolized monkeypox virus.A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.In vitro efficacy of brincidofovir against variola virus.TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Development of CMX001 for the Treatment of Poxvirus Infections.Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Therapeutic and prophylactic drugs to treat orthopoxvirus infections Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.Orthopoxvirus targets for the development of new antiviral agents.Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Animal models of orthopoxvirus infection.The search for new therapies for human cytomegalovirus infections.Highlights in antiviral drug research: antivirals at the horizon.Cidofovir Activity against Poxvirus Infections.Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins.Evaluation of Taterapox Virus in Small Animals.Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.Protective murine and human monoclonal antibodies against eczema vaccinatum The French Armed Forces Virology Unit: A Chronological Record of Ongoing Research on Orthopoxvirus.Challenges and Achievements in Prevention and Treatment of Smallpox.

P2860

Q21131362-5053CD0B-8F6E-4EE3-BCA4-967ABEC588DB Q24629979-360C5941-A9E0-4EF5-B436-96A47DF85A25 Q27000998-84CF4835-F237-4067-8E97-77576DFB3161 Q28384852-C04307A3-9AAB-49C2-A9A6-8273F902E3C5 Q31045190-F2A07756-3AF4-4B50-8B13-54D8C2A2F011 Q33570349-E4E73744-55D3-4C56-B5BD-57351A67A2B6 Q33617625-361B4A2D-EB8B-49CD-A202-D6C6FFB77CC5 Q33769393-C8FA635C-2E81-4620-938C-FFEB4B6C5133 Q34057540-4E6192CB-9C30-432D-8ADA-C1A4B613714B Q34414790-46DBE726-DB4D-4A43-A070-560E3F020B1C Q34432037-B8A67ECF-74B1-4A1D-AB2B-FBAB2DB77B0E Q34469836-49B1504D-C636-488A-8222-E2BC22C73DC1 Q34801704-1458655F-BB9E-4C7B-A0B9-00C4C4F6CF4E Q35110971-9EC25C60-D69C-48FF-978D-6627304315DD Q35260316-FFCFDC8A-097A-4A03-8BD8-40595C19B9F6 Q35261304-F5F088FF-4B60-4CD2-A87F-AD8C056C212D Q35270714-43F0C7F8-550E-43D7-9CCC-1319B3162A00 Q35598919-F70810BF-85FD-415E-B591-395B3BF42C68 Q36130201-C8E6C8FE-0202-4D26-A131-103E94EC07DB Q37009973-AAF4CD40-B352-4342-83D9-319895E1AFA9 Q37043625-1D03C151-4756-4D77-865A-F8C270375C3C Q37062384-397FDB97-E269-40CC-AD45-DD39D57D6CA5 Q37072113-9BF4AD91-F1F3-486F-AC05-04128CD0596E Q37173398-6C9A618A-5BD0-472F-962F-1E4118B8A4DC Q37331541-A1717312-98C9-42A4-95E0-ED4EF7168A99 Q37401749-5DBB77D9-599F-4A11-9ADB-62740CAA9C49 Q37593480-3A567699-9B67-44CB-A534-005DB30FEEEA Q37777545-2C4E62EA-3B17-45CA-9F67-00FA3E061AA2 Q37811458-24EAC539-E3C4-4788-85E3-A8D90169BBD4 Q38007145-84FA3113-651F-4466-AB16-D224558565D0 Q38614278-BA510B9D-E134-47E7-B150-1F1A28CF197E Q38957078-BF25D380-C95E-45E3-9189-0F27BF5A0E4E Q39758342-4ABF1649-B6FD-4EC1-8156-49F4AB8FEC70 Q40099794-8F2DDA45-A3C6-4865-AE01-EAC315F589A2 Q41361126-68FEDC82-45F9-4557-A41D-3F69D3051DA6 Q42638248-E3A47FEE-457B-47F6-A65F-62C6BCCE53E2 Q47237554-C34839D7-372B-422A-8704-0B3EE52649FC Q47547852-5F1B91F2-C80F-4577-BB84-EF04108B0936

P2860

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.

http://www.wikidata.org/entity/Q38460330

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Efficacy of therapeutic interv ...... 1) in a lethal mousepox model.

@en

type

label

Efficacy of therapeutic interv ...... 1) in a lethal mousepox model.

@en

prefLabel

Efficacy of therapeutic interv ...... 1) in a lethal mousepox model.

@en

P1433

Q38460330-E2040743-7E45-4560-86DF-C748873D9618

P1476

Q38460330-BB96508E-B817-45BB-B417-9D94A6601A5A

P2093

Q38460330-3A37C66C-F2A7-41F8-9772-B321E3865AA0

Q38460330-4CB413E5-FA4A-4ACF-8030-74070F47618F

Q38460330-548F98A5-4AB3-4F4C-964C-43C64834EAD1

Q38460330-5AAC1A8F-C323-4B1E-8A6C-6A33701C4FF7

Q38460330-7AE33BEA-9788-46B1-9E78-48DA8D18E911

Q38460330-B29785E2-DEC0-4530-BE6A-EFBF620B1BE4

Q38460330-D3D348F0-E820-4F3B-A6BC-BC88B1C48C75

Q38460330-E007D248-C0FE-45D0-8EDF-6A259C99DE64

Q38460330-F2F3B2F1-D6E1-4ECC-8F92-A9D0E3B5DBB5

P304

Q38460330-3D7989B5-1BDD-4A23-ADCC-558E05FDAB96

P31

Q38460330-888350A2-C63C-40C8-9AE4-3B10365EB70E

P356

Q38460330-8463598B-A810-4917-B149-7F9B338CAEB7

P433

Q38460330-A82DE88C-E0F3-43F6-9261-E3F6633F5D1D

P478

Q38460330-4B4FBB9E-AF26-4B1D-B960-DC4E3E5E4F36

P577

Q38460330-B009D716-C109-45BE-A6E6-C4BAD6065F33

P5875

Q38460330-F0F8CEE7-7859-416B-BDD1-E419E9814C3B

P698

Q38460330-EE6A648A-5350-4ADE-9B71-0A91640E54FA

P356

J.ANTIVIRAL.2007.08.003

P1433

Antiviral Research

P1476

Efficacy of therapeutic interv ...... 1) in a lethal mousepox model.

@en

P2093

Alice Robertson

http://www.w3.org/2001/XMLSchema#string

Bernhard Lampert

http://www.w3.org/2001/XMLSchema#string

Christina Oberle

http://www.w3.org/2001/XMLSchema#string

Erin Touchette

http://www.w3.org/2001/XMLSchema#string

George Painter

http://www.w3.org/2001/XMLSchema#string

Lawrence C Trost

http://www.w3.org/2001/XMLSchema#string

Merrick Almond

http://www.w3.org/2001/XMLSchema#string

R Mark Buller

http://www.w3.org/2001/XMLSchema#string

Scott Parker

http://www.w3.org/2001/XMLSchema#string

P304

39-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ANTIVIRAL.2007.08.003

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5941146

http://www.w3.org/2001/XMLSchema#string

P698

17904231

http://www.w3.org/2001/XMLSchema#string